Abstract
Secreted proteins are an attractive minefield for cancer drug targets. An iTRAQ-based tandem mass spectrometry approach was employed to relatively quantify proteins in the secretomes of four isogenic breast cancer cell lines with increasing metastatic potential. CXCL3 was found to be upregulated in aggressive cancer cells. SiRNA and antibody neutralization studies supported a role of CXCL3 in metastatic processes. Meta-analysis of the mRNA level of CXCL3 in 1881 breast tumors supported a role of CXCL3 in clinical breast cancer. Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
Keywords: Breast cancer, chemokine, CXCL3, migration, proteomics, secretome.
Current Cancer Drug Targets
Title:CXCL3 is a Potential Target for Breast Cancer Metastasis
Volume: 14 Issue: 3
Author(s): Amanda Lay Pin See, Poh Kuan Chong, Ssu-Yi Lu and Yoon Pin Lim
Affiliation:
Keywords: Breast cancer, chemokine, CXCL3, migration, proteomics, secretome.
Abstract: Secreted proteins are an attractive minefield for cancer drug targets. An iTRAQ-based tandem mass spectrometry approach was employed to relatively quantify proteins in the secretomes of four isogenic breast cancer cell lines with increasing metastatic potential. CXCL3 was found to be upregulated in aggressive cancer cells. SiRNA and antibody neutralization studies supported a role of CXCL3 in metastatic processes. Meta-analysis of the mRNA level of CXCL3 in 1881 breast tumors supported a role of CXCL3 in clinical breast cancer. Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
Export Options
About this article
Cite this article as:
See Lay Pin Amanda, Chong Kuan Poh, Lu Ssu-Yi and Lim Pin Yoon, CXCL3 is a Potential Target for Breast Cancer Metastasis, Current Cancer Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1568009614666140305222328
DOI https://dx.doi.org/10.2174/1568009614666140305222328 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Specific Active Immunotherapy of Cancer: Potential and Perspectives
Reviews on Recent Clinical Trials Editorial (Thematic Issue: Treatment of Cancer in the Elderly)
Anti-Cancer Agents in Medicinal Chemistry Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Synthesis and Evaluation of a New Series of Arylidene Indanones as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Modeling Study of Phenylsulfonylfuroxan Derivatives as P-gp Inhibitors: A Combined Approach of CoMFA, CoMSIA and HQSAR
Anti-Cancer Agents in Medicinal Chemistry Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention
Current Pharmaceutical Design Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial
Reviews on Recent Clinical Trials IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin
Pharmaceutical Nanotechnology Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Preface
Current Pharmaceutical Design Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Can Dietary Antioxidants Reduce the Incidence of Brain Tumors?
Current Drug Metabolism Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
CNS & Neurological Disorders - Drug Targets MicroRNAs: The New Challenge for Traumatic Brain Injury Diagnosis
Current Neuropharmacology Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Gene Therapy of Cancer with Interleukin-12
Current Pharmaceutical Design Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design